Resummation of fermionic in-medium ladder diagrams to all orders

A system of fermions with a short-range interaction proportional to the scattering length $a$ is studied at finite density. At any order $a^n$, we evaluate the complete contributions to the energy per particle $\bar E(k_f)$ arising from combined (multiple) particle-particle and hole-hole rescatterings in the medium. This novel result is achieved by simply decomposing the particle-hole propagator into the vacuum propagator plus a medium-insertion and correcting for certain symmetry factors in the $(n-1)$-th power of the in-medium loop. Known results for the low-density expansion up to and including order $a^4$ are accurately reproduced. The emerging series in $a k_f$ can be summed to all orders in the form of a double-integral over an arctangent function. In that representation the unitary limit $a\to \infty$ can be taken and one obtains the value $\xi= 0.5067$ for the universal Bertsch parameter. We discuss also applications to the equation of state of neutron matter at low densities and mention further extensions of the resummation method.Comment: 12 pages, 7 figures, submitted to Nuclear Physics

Range corrections for two-neutron halo nuclei in effective theory

The range corrections to the universal properties and structure of two-neutron halo nuclei are investigated within an effective quantum mechanics framework. Treating the nucleus as an effective three-body system, we make a systematic improvement upon previous calculations by calculating the linear range corrections at next-to-leading order. Since the effective ranges for the neutron-core interactions are not known, we estimate the effective range to be set by the inverse of the pion mass. We investigate the possibility of excited Efimov states in two-neutron halo nuclei and calculate their mean square radii to next-to-leading order. We find that the effective range corrections are generally small and the leading order predictions are very robust.Comment: 19 pages, 4 eps figures, revtex4, final version to appear in Nucl. Phys.

The two-nucleon system at next-to-next-to-next-to-leading order

We consider the two-nucleon system at next-to-next-to-next-to-leading order (N^3LO) in chiral effective field theory. The two-nucleon potential at N^3LO consists of one-, two- and three-pion exchanges and a set of contact interactions with zero, two and four derivatives. In addition, one has to take into account various isospin-breaking and relativistic corrections. We employ spectral function regularization for the multi-pion exchanges. Within this framework, it is shown that the three-pion exchange contribution is negligibly small. The low-energy constants (LECs) related to pion-nucleon vertices are taken consistently from studies of pion-nucleon scattering in chiral perturbation theory. The total of 26 four-nucleon LECs has been determined by a combined fit to some np and pp phase shifts from the Nijmegen analysis together with the nn scattering length. The description of nucleon-nucleon scattering and the deuteron observables at N^3LO is improved compared to the one at NLO and NNLO. The theoretical uncertainties in observables are estimated based on the variation of the cut-offs in the spectral function representation of the potential and in the regulator utilized in the Lippmann-Schwinger equation.Comment: 62 pp, 13 fig

Few Body Reserch - Summary

Few-body research history, achievements, current development and challenges are presented.Comment: 21 pages, 2 tables, Summary talk at 18th International IUPAP Conference on Few-Body Problems in Physics August 21-26. 2006 Santos SP Brazil; to be published in Nuclear Physic

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402